Oral delivery of a therapeutic gene encoding glucagon-like peptide 1 to treat high fat diet-induced diabetes
- Authors
- Nurunnabi, Md; Lee, Seung-Ah; Revuri, Vishnu; Hwang, Yong Hwa; Kang, Sung Hun; Lee, Minhyung; Cho, Sungpil; Cho, Kwang Jae; Byun, Youngro; Bae, You Han; Lee, Dong Yun; Lee, Yong-Kyu
- Issue Date
- Dec-2017
- Publisher
- ELSEVIER
- Keywords
- Diabetes; Peptide nanoparticle; Oral delivery; Hypoglycemia; Anti-obesity
- Citation
- JOURNAL OF CONTROLLED RELEASE, v.268, pp.305 - 313
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CONTROLLED RELEASE
- Volume
- 268
- Start Page
- 305
- End Page
- 313
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5336
- DOI
- 10.1016/j.jconrel.2017.08.035
- ISSN
- 0168-3659
- Abstract
- The number of people suffering from insulin-independent type 2 diabetes mellitus (T2DM) is ever increasing on a yearly basis. Current anti-diabetic medications often result in adverse weight gain and hypoglycemic episodes. Hypoglycemia can be avoided with glucagon-like peptide (GLP)-1 receptor agonists, which are expensive and require daily injections that may result immune activation. This study demonstrates the use of non-viral vector based oral delivery of GLP-1 gene through enterohepatic recycling pathways of bile acids. Oral administration of the plasmid DNA (pDNA) encoding GLP-1 decreased diabetic glucose levels to the normoglycemic range with significant weight reduction in a high-fat diet (HFD) induced diabetic mouse model and a genetically engineered T2DM rat model. This novel oral GLP1 delivery system is an attractive alternative to treat late-stage T2DM conditions that require repeated insulin injection and can potentially minimize the occurrence of hypoglycemic anomalies.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 공과대학 > 서울 생명공학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5336)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.